in vitro and in vivo models to study mechanisms, interventions and biomarkers
in metabolic diseases and their complications.
Metabolic Health Research (MHR) at TNO
MHR develops and performs in vitro and in vivo models to study mechanisms, interventions and biomarkers in metabolic diseases and their complications.
These translational models include unique (humanized) transgenic mouse models, in vivo and in vitro models, read-out systems employing i.a. histology, biochemical assays, cell biology, molecular biology, immunology and inflammation markers.
This preclinical research is strongly translational and aims to improve the predictability of efficacy and safety of pharmaceutical and food interventions by detailed knowledge of disease processes and mechanisms.
MHR has a track record in applied science, study design, professional project management and quality systems.
MHR offers customized services that can be tailored to customer needs by direct interaction of scientists of MHR and the customer.
We also propose partnering opportunities to gain a deeper understanding of the following points:
● Elucidation of disease mechanisms at the molecular level
● Elucidation of organ cross talk during the disease onset process
● Identification of novel biomarkers
Disease area of Interest (and link)
● Obesity, MASLD / MASH
● Sarcopenia / Frailty
● Cardiovascular-Kidney-Metabolic (CKM) syndrome・Heart Failure（HFpEF）
● Woman's Health (Endometoriosis, Menopause, etc)
Cardiovascular-Kidney-Metabolic (CKM) syndrome model
Cardiovascular-Kidney-Metabolic (CKM) Syndrome is a complex disorder involving CVD, kidney disease, type 2 diabetes and obesity.
These conditions share risk factors and can exacerbate each other. Development of new therapies is hampered by the lack of translational models.
A novel diet induced hypertension-accelerated mouse model with obesity, diabetes and hypertension was developed which shows diabetic and chronic kidney disease (DKD/CKD) and heart failure with preserved ejection fraction (HFpEF).
Male KKAy mice on HFD and LNNA developed DKD resulting in CKD and HFpEF.
Combination therapy with Lisinopril and Dapagliflozin rescued GFR decline and reduced renal and cardiac damage.
This indicates the clinical relevance of the model allowing holistic and mechanistic studies in both early and more advanced stages of CKM Syndrome.
Features for Cardiovascular-Kidney-Metabolic (CKM) syndrome model
・Progressive decline in renal function in setting of hyperglycemia,
typically preceded by a period of glomerular hyperfiltration.
・Quick onset of Albuminuria
・Pathological changes in kidneys:
> Glomerular basement membrane thickening
> Mesangial matrix expansion and sclerosis
> Tubulo-interstitial fibrosis
> Arteriolar hyalinosis
・Diet induced (Human-like diet composition)
・The model shows hyperlipidemia, hyperglycemia and hypertension, albuminuria, decline in GFR and typical histological features of DKD.
・The model also shows Coronary calcification, Myocardial fibrosis, HFpEF and HFrEF as observed in Heart Failure.
・Reference control: Combination of ACE inhibitor + SGLT2 ihibitor
Readout parameters
・Metabolic parameter: BW, F&W-intake, Glucose, Insulin, CHO, TG
・Function: Diuresis, Albuminuria, UACR, GFR by TD inulin clearance
・Pathology: Quantitative scoring of Glomerular and Tubular damage, Liver and Cardiac damage
・Optional: Proteomics/Metabolomics,Next generation sequencing, EM microscopy, PEMP analysis (NIPOKA)
Download Publication
□
A novel mouse model for cardiovascular-kidney-metabolic syndrome: bridging metabolic, renal and cardiac dysfunction.
Molecular Metabolism. Apr, 2026
□
Treatment with Either SGLT2 Inhibitors or GLP-1 Receptor Agonists Rescues GFR Decline in a Multifactorial Cardiovascular-Kidney-Metabolic Syndrome Mouse Model. Journal of the American Society of Nephrology. Oct, 2025
□
Standard-of-care combination therapy rescues GFR decline and cardiac damage in a novel cardiovascular-kidney-metabolic syndrome mouse model
□
Combination therapy with Lisinopril and Dapagliflozin rescues GFR decline and glomerular damage in the advanced DKD/CKD KKAY mouse model.
□
Cardiac damage in DKD/CKD mouse model resembles HFpEF and can be reduced by Standard-of-care treatment.
Women's Health；Health and lifestyle
Our understanding of the female body and its unique healthcare needs remains surprisingly limited. Many drugs are mainly tested on men, and it was only recently that female-specific heart disease symptoms were recognized. Conditions like endometriosis often take an average of 10 years to diagnose. This health disparity also impacts labour productivity, costing billions globally.
TNO's Women's Health program integrates our biomedical, (psycho)social, and technological expertise to tackle women's health challenges. By merging fundamental research with practical solutions, we aim to ensure that future generations of women can achieve their full potential without health-related barriers. However, this goal cannot be reached in isolation.
We collaborate with healthcare professionals, employers, researchers, policymakers, and companies, including those in the food, pharmaceutical and technology sectors.
Current co-development & collaboration opportunities
● Endometriosis: early warning system biomarkers, microbiome and efficacy testing.
● Muscle aging and frailty: cardiac disease, frailty and sarcopenia, optimal performance and sustained employability throughout life.
● Menopause and sex hormones: Key disease drivers and efficacy testing on fibrosis.
● Vaginal health: new in-vitro screenings model.
● Women, work and family health: scan for employers, life cycle perspective on employability, systemic interventions (community approaches, chain approaches), eHealth technologies.
Fibrosis models
・Lung Bleomycin-induced lung fibrosis model in mice
(Feature：o.p.administration, low variation and motality）
・Skin Bleomycin-induced skin fibrosis model in mice.
・Liver CCL4-induced, Diet-induced model in mice
・Kidney UUO model in mice.
・in vitro fibrosis assay with the fibrosis patient samples
Myoblast differenciation, Fibroblast proliferation, Migration
Current co-development & collaboration opportunities
● Development of Novel Blood-Based Biomarkers for IPF
Recent publication: Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs
We're open to discuss;
・Collagen type analysis：Collagen 1α1, 3α1, 4α1, 5α1, 6α2.
・Signatutre analysis involving newly synthetised collagen
Reference
□ Collagen quantification in cell cultures and tissues.
